ARISE

PREVU* POC Skin Sterol Test is part of AtheroGenics’ multi-site phase III ARISE trial. ARISE will enroll 4,000 patients at approximately 180 cardiac centers throughout the United States, Canada, the United Kingdom and South Africa. The collected data will quantify the relationship between skin cholesterol and primary cardiovascular events, such as heart attack, AtheroGenics’ AGI-1067 drug and other risk factors, including serum lipids and patient demographics. The trial will provide valuable primary-event data and broad exposure of PREVU* POC to leading cardiologists and cardiac centers worldwide.